Theodosia Vallianatou

Dr. Theodosia Vallianatou

Uppsala University
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2019 in Nature Methods
Verified
Journal Article
Closed access
PDF file
MSMohammadreza Shariatgorji
Mohammadreza Shariatgorji
ANAnna Nilsson
Anna Nilsson
EFElva Fridjonsdottir
Elva Fridjonsdottir
TVTheodosia Vallianatou
Theodosia Vallianatou
PKPatrik Källback
Patrik Källback
PAPer E. Andrén
Per E. Andrén

19 December 2014 in Analytical Chemistry
Verified
Journal Article
Closed access
ANAnna Nilsson
Anna Nilsson
RGRichard J. A. Goodwin
Richard J. A. Goodwin
MSMohammadreza Shariatgorji
Mohammadreza Shariatgorji
TVTheodosia Vallianatou
Theodosia Vallianatou
PWPeter J. H. Webborn
Peter J. H. Webborn
PAPer E. Andrén
Per E. Andrén

1 June 2015 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
GLGeorge Lambrinidis
George Lambrinidis
TVTheodosia Vallianatou
Theodosia Vallianatou
ATAnna Tsaantili
Anna Tsaantili

1 August 2016 in NeuroImage
Verified
Journal Article
Closed access
MSMohammadreza Shariatgorji
Mohammadreza Shariatgorji
Nicole StrittmatterNicole Strittmatter
Nicole Strittmatter
ANAnna Nilsson
Anna Nilsson
PKPatrik Källback
Patrik Källback
AAAlexandra Alvarsson
Alexandra Alvarsson
PAPer E. Andren
Per E. Andren

8 January 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
EFElva Fridjonsdottir
Elva Fridjonsdottir
RSReza Shariatgorji
Reza Shariatgorji
ANAnna Nilsson
Anna Nilsson
TVTheodosia Vallianatou
Theodosia Vallianatou
LOLuke Odell
Luke Odell
PAPer E. Andrén
Per E. Andrén
L-DOPA treatment for Parkinson’s disease frequently leads to dyskinesias, the pathophysiology of which is poorly understood. We used MALDI-MSI to map the distribution of l-DOPA and monoaminergic pathways in brains of dyskinetic and nondyskinetic primates. We report elevated levels of l-DOPA, and its metabolite 3-O-methyldopa, in all measured brain regions of dyskinetic animals and increases in dopamine and metabolites in all regions analyzed except the striatum. In dyskinesia, dopamine levels correlated well with l-DOPA levels in extrastriatal regions, such as hippocampus, amygdala, bed nucleus of the stria terminalis, and cortical areas, but not in the striatum. Our results demonstrate that l-DOPA–induced dyskinesia is linked to a dysregulation of l-DOPA metabolism throughout the brain. The inability of extrastriatal brain areas to regulate the formation of dopamine during l-DOPA treatment introduces the potential of dopamine or even l-DOPA itself to modulate neuronal signaling widely across the brain, resulting in unwanted side effects.

26 July 2023 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
IKIbrahim Kaya
Ibrahim Kaya
ANAnna Nilsson
Anna Nilsson
DLDominika Luptáková
Dominika Luptáková
YHYachao He
Yachao He
TVTheodosia Vallianatou
Theodosia Vallianatou
PAPer E. Andrén
Per E. Andrén
Metabolism of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) to the neurotoxin MPP+ in the brain causes permanent Parkinson’s disease-like symptoms by destroying dopaminergic neurons in the pars compacta of the substantia nigra in humans and non-human primates. However, the complete molecular pathology underlying MPTP-induced parkinsonism remains poorly understood. We used dual polarity matrix-assisted laser desorption/ionization mass spectrometry imaging to thoroughly image numerous glycerophospholipids and sphingolipids in coronal brain tissue sections of MPTP-lesioned and control non-human primate brains (Macaca mulatta). The results revealed specific distributions of several sulfatide lipid molecules based on chain-length, number of double bonds, and importantly, hydroxylation stage. More specifically, certain long-chain hydroxylated sulfatides with polyunsaturated chains in the molecular structure were depleted within motor-related brain regions in the MPTP-lesioned animals, e.g., external and internal segments of globus pallidus and substantia nigra pars reticulata. In contrast, certain long-chain non-hydroxylated sulfatides were found to be elevated within the same brain regions. These findings demonstrate region-specific dysregulation of sulfatide metabolism within the MPTP-lesioned macaque brain. The depletion of long-chain hydroxylated sulfatides in the MPTP-induced pathology indicates oxidative stress and oligodendrocyte/myelin damage within the pathologically relevant brain regions. Hence, the presented findings improve our current understanding of the molecular pathology of MPTP-induced parkinsonism within primate brains, and provide a basis for further research regarding the role of dysregulated sulfatide metabolism in PD.